MedTrace Logo

Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)

NCT07055880 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-09

No results posted yet for this study

Summary

To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.

Conditions

  • Rabies

Interventions

BIOLOGICAL

Rabies Vaccine (Serum-free Vero Cell), Freeze-dried

Receiving five doses of rabies vaccine manufactured by Sinovac using the "Essen" PEP schedule

BIOLOGICAL

Verorab®

Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the "Essen" PEP schedule

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ali Faisal Saleem · Vice Chair, Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan

  • Nosheen Nasir, Dr. · Aga Khan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-28
Primary Completion
2026-01-15
Completion
2026-01-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07055880 on ClinicalTrials.gov